Published in final edited form as:

Am J Psychiatry. 2014 March 1; 171(3): 350–359. doi:10.1176/appi.ajp.2013.11121766.

Revisiting Schizophrenia Linkage Data in the NIMH Repository: Reanalysis of Regularized Data Across Multiple Studies

Veronica J. Vieland, Ph.D.¹, Kimberly A. Walters, Ph.D.¹, Thomas Lehner, Ph.D.³, Marco Azaro, Ph.D.², Kathleen Tobin, Ph.D.², Yungui Huang, Ph.D.¹, and Linda M. Brzustowicz, M.D.²

¹Battelle Center for Mathematical Medicine, The Research Institute at Nationwide Children's Hospital, Columbus, OH

²Department of Genetics, Rutgers University, Piscataway, NJ

³The National Institute of Mental Health, Bethesda, MD

Abstract

Objective—The Combined Analysis of Psychiatric Studies (CAPS) project conducted extensive review and regularization across studies of all schizophrenia linkage data available as of 2011 from the NIMH-funded Center for Collaborative Genomic Studies on Mental Disorders, also known as the Human Genetics Initiative (HGI). Here we reanalyze the data using statistical methods tailored to accumulation of evidence across multiple, potentially highly heterogeneous, sets of data.

Method—Data were subdivided based on contributing study, major population group, and presence or absence within families of schizophrenia with a substantial affective component. The Posterior Probability of Linkage (PPL) statistical framework was used to sequentially update linkage evidence across these data subsets (omnibus results).

Results—While some loci previously implicated using the HGI data were also identified in our omnibus analysis (2q36.1, 15q23), others were not. Several loci were found that had not been previously reported in the HGI samples, but which are supported by independent linkage and/or association studies (3q28, 12q23.1, 11p11.2, Xq26.1). Not surprisingly, differences were seen across population groups. Of particular interest are signals on 11p15.3, 11p11.2, and Xq26.1, for which families with substantial affective component support linkage while the remaining families give evidence against linkage. All three of these loci overlap with loci reported in independent studies of bipolar disorder or mixed bipolar-schizophrenia samples.

Conclusions—Public data repositories provide the opportunity to leverage large, multi-site data sets for studying complex disorders. Analysis with a statistical method specifically designed for such data enables us to extract new information from an existing data resource.

Corresponding Author: Veronica J. Vieland, Ph.D., Battelle Center for Mathematical Medicine, The Research Institute at Nationwide Children's Hospital, 575 Children's Crossroad, Columbus, OH 43215, veronica.vieland@nationwidechildrens.org.

Dr. Brzustowicz serves as a consultant for the Janssen Pharmaceutical Companies of Johnson & Johnson. All remaining authors report no competing interests.

Introduction

For the past two decades, NIMH-funded investigators conducting genetic research have been strongly encouraged to contribute biospecimens, along with whatever corresponding genotypic and phenotypic information they have assembled, to a centralized repository housed at the Center for Collaborative Genomic Studies on Mental Disorders. The repository grows immortalized cell lines, supplies DNA to researchers, and also provides downloadable copies of clinical and genotypic data files through the Human Genetics Initiative (HGI) (see nimhgenetics.org). We report here the first wave of results from the HGI's Combined Analysis of Psychiatric Studies (CAPS) project, which is undertaking extensive data review and analysis of data in the repository. The focus of this report is reanalysis of the seven separate schizophrenia family studies that had deposited genotypic and phenotypic data with the repository as of April 2011.

The CAPS project is specifically funded to reanalyze HGI data using the PPL framework, as implemented in the software package KELVIN (1). (PPL originally stood for Posterior Probability of Linkage, which is the KELVIN statistic reported here, although KELVIN can compute other quantities including association statistics.) There are three principle advantages to using the PPL for linkage analysis of the HGI data (see Methods for details):

- i. It is essentially model-free, while retaining the advantages of likelihood-based analyses, making full use of all available data including unaffected individuals.
- ii. It is specifically tailored to handle multiple, potentially highly heterogeneous data sets or subsets, using Bayesian sequential updating to accumulate linkage evidence across subsets while allowing explicitly for genetic differences between subsets.
- iii. In stark contrast to p-values or maximum LODs, based on either "mega-analysis" or traditional meta-analysis, the PPL can accumulate evidence both for and against linkage at each genomic position. This increases resolution of a genome scan by excluding stretches of the genome in an essentially model-free manner, while also distinguishing common versus distinct genetic features across different populations or clinical subgroups, as we discuss below.

Thus the PPL is uniquely well-suited to the analysis of multi-site, potentially highly heterogeneous genetic data. Here we consider omnibus linkage results, based on all of the HGI schizophrenia family data in aggregate. We also consider population-specific findings, and the possibility of specific loci underlying a clinical schizophrenia subtype involving affective components.

Methods

Data Classification and Subsetting

Data for all multiplex pedigrees with available genome-wide genotyping available as of April 2011 were downloaded from the HGI. Families in the download came from seven different studies (2–9), labeled here as Study 1- Study 7. An extensive data regularization protocol was applied to both genotypic and phenotypic information as downloaded from the HGI. This included applying strict criteria to the DSM diagnostic codes provided to the HGI

by the individual studies to define a narrow Schizophrenia phenotype and a Schizophrenia/Affective phenotype, which included schizoaffective disorder or any schizophrenia disorder and a significant affective disorder. (See SA1, SA2 for details of genotype and phenotype processing, respectively.)

Families were included in the current analyses if they contained at least one case of Schizophrenia, at least one additional case of either Schizophrenia or Schizophrenia/Affective, and at least 2 affected genotyped individuals. This left 970 multiplex families for analysis, containing 4,023 phenotyped individuals (average 4.1 per pedigree) and 4,208 genotyped individuals (average 4.3 per pedigree). (See ST1 for annotated list of families included/excluded from these analyses.) We elected to use stringent diagnostic and inclusion criteria in order to minimize clinical heterogeneity within data subsets, and especially, in order to minimize the effects of clinical differences across studies. Such differences may tend to be more pronounced for broad spectrum conditions than for the core diagnoses.

We grouped families into subsets by study and population (African American, European American, Han Chinese, Hispanic). Each of the original studies either contained a single group, or in the cases of Study 1 (2, 3) and Study 2 (4), divided their own analyses by European American versus African American families in published analyses. Thus these subgroupings match previous treatments of the data sets.

Additionally, because schizophrenia with a significant affective component is now considered as a potentially genetically distinct form of schizophrenia, we further subdivided the data based on the presence or absence of any individuals with Schizophrenia/Affective within the pedigree. (When referring to families, “Schizophrenia” refers to families whose affected members are all classified as Schizophrenia; and Schizophrenia/Affective refers to families in which at least one affected individual is classified as Schizophrenia/Affective.) While it is impossible to distinguish a family that would never have produced a case meeting Schizophrenia/Affective criteria from a family that, by chance, failed to manifest this affective phenotype among the small number of affected individuals present, even an imperfect classifier can be helpful in detecting linkage in one but not the other group (10).

Several of the studies had multiple data collection sites, and “site” itself might demarcate more homogeneous subsets of the data. However, further subdivision by site results in sample sizes that are too small for meaningful analysis (< 10 small families/data set), and for this reason we did not subset based on site. ST2 shows sample sizes by subset.

Statistical Methods

All analyses were conducted using the software package KELVIN (1), which implements the PPL class of models for measuring the strength of genetic evidence. The specific statistic employed here was the PPL itself (posterior probability of linkage). The PPL is essentially a straightforward application of Bayes’ theorem. Letting L represent “linkage” to a given genomic position and D be the data, the PPL is calculated as

$$PPL = P(L|D) = \frac{P(D|L)P(L)}{P(D|L)P(L) + P(D|no L)P(no L)}.$$

The two likelihoods (P) appearing in this equation, $P(D|L)$ and $P(D|no L)$, are the numerator and denominator, respectively, of the exponentiated ordinary LOD score. They are functions of the parameters of the unknown trait model, and what distinguishes the PPL as computed by KELVIN is the way in which these parameters are handled within and across data subsets, as described below.

The PPL is on the probability scale (0,...,1) and as applied here it represents the probability of a schizophrenia gene at each location, given the available data. For the microsatellite data, 4-point (3 marker) multipoint calculations were run; for the SNP data, full multipoint analysis using all markers was used. See (1) for technical details and for all primary references to the supporting theoretical literature; see (11–13) for examples of previous applications.

The PPL is based on an approximating single-locus likelihood allowing for within-sample heterogeneity using the admixture parameter α of Smith (14). All parameters of the trait model including α are integrated out of the PPL using (independent) uniform priors on each parameter (see (1) for details), implicitly allowing for dominant, recessive or intermediate models. This provides a robust approximation for mapping complex traits in terms of the marginal model at each locus, and because the parameters are integrated out, no specific assumptions regarding their values are required.

The PPL framework accumulates evidence across data subsets by integrating the trait parameters out of the likelihood separately for each subset (allowing their values to differ across subsets), then using Bayesian sequential updating to carry the posterior linkage evidence from previously analyzed data forward as prior evidence as new data subsets are analyzed, at each genomic position in turn. This allows for differences in allele frequencies, penetrances (due to background genetic and/or environmental differences across subsets), and also chance fluctuations in the proportion of “linked” pedigrees at a given locus. The order in which data sets are analyzed does not affect the final result. In the presence of appreciable heterogeneity, sequential updating is far more robust in retaining true signals originating from individual subsamples than analyses that simply combine subsets for a single analysis (10, 15, 16). It is also substantially more sensitive in detecting true genetic effects across heterogeneous disorders than standard meta-analyses (17, 18). Moreover, the PPL accumulates evidence *against* linkage as well as in favor of linkage. Thus, inspection of subset-specific contributions to the omnibus signal can distinguish among subsets that are (perhaps only weakly) supporting linkage and subsets that are actually contributing evidence against linkage, as we illustrate below. Here we sequential updated across data subsets defined by study (Study 1–Study 7), major population group (African American, European American, Han Chinese, Hispanic) and clinical type (presence or absence of any individual meeting Schizophrenia/Affective criteria within the family).

The PPL is on the probability scale, and its interpretation is therefore straightforward: e.g., PPL=40%, means that there is an estimated 40% probability of a trait gene at the given location based on these data. Based on (19), the prior probability at each location is set to 2%, so that PPLs > 2% indicate (some degree) of evidence in favor of a trait gene at the locus, while PPLs < 2% represent evidence against the location. This prior probability is based on empirical data (19), and because it is calculated as the probability of linkage between a random marker location and a single disease gene, it is conservative for multi-locus disorders. The PPL is a measure of statistical evidence, not a decision-making procedure; therefore, there are no “significance levels” associated with it, and it is not interpreted in terms of associated error probabilities (20, 21). By the same token, no multiple testing corrections are applied to the PPL, just as one would not “correct” a measure of the temperature made in one location for readings taken at different locations (22). Nevertheless, it may assist readers to have some sense of scale relative to more familiar frequentist test statistics. In simulations of 10,000 replicates of sets of 1,000 affected sib-pairs (the predominant data structure in these analyses) under the null hypothesis (no linkage), “significance” cutoffs of PPL = 5%, 10%, 15%, or 25% were associated with Type 1 error probabilities (the rate at which the PPL crossed the given threshold under the null) of 0.0070, 0.0011, 0.0004, and 0.0001, respectively. In Results, we highlight loci with PPL 25%; complete results are given in ST3.

Results

We first (i) present omnibus linkage results, considering all of the data in aggregate. We then consider common and distinct loci by (ii) major population group and (iii) by clinical subgroup (families with narrow Schizophrenia only vs. families containing at least one case of Schizophrenia/Affective). We then (iv) compare our results with results from the original publications for Study 1–Study 7 and (v) with results based on independent sets of data and meta-analyses.

(i) Omnibus results

Figure 1 shows omnibus linkage results, sequentially updated across all data subsets. Overall, 76% of the genome showed evidence against linkage (PPL < 0.02), while only 10% showed PPL > 0.05 and 4% showed PPL > 0.1. There were twenty distinct loci with PPL > 0.1, 13 with PPL > 0.15, and 4 with PPL > 0.25. These last occurred at 2q36.1 (PPL=0.41), 3q28 (PPL=0.27), 12q23.1 (PPL=0.26), and 15q23 (PPL=0.27) (Table 1).

(ii) Population-specific results

Figure 2 shows population-specific results. There are 4 population-specific loci with PPL > 0.25 (Table 1). Two of these come from Han Chinese (10q22.3, PPL = 0.36; 10q26.12, PPL = 0.34), and at both these loci all three of the other population groups show evidence against linkage. Similarly, European American supports 1p32.3 (PPL = 0.27), with all other population groups giving evidence against linkage at this locus. By contrast, the Hispanic-specific peak at 5p14.1 (PPL = 0.26) receives modest support from African American (PPL=.04) but evidence against linkage in the other two sets. The 4 omnibus peaks (discussed in (i) above) are each supported by at least 3 population groups, in each case with

the remaining group being neutral, i.e., showing evidence neither for or against linkage (Table 1).

(iii) Clinical subset-specific results

Figure 3 shows results by clinical subgroup. There are 5 loci with PPL > .25 in either of the two clinical subgroups (Table 1), and in every case the other subgroup gives evidence against linkage (in each case, PPL < 0.01). Notably, 3 of these peaks (11p15.3, 11p11.2, 23q26.1) are supported by the far smaller Schizophrenia/Affective subset, suggesting that this really does constitute a more homogeneous classification of the families. However, there is possible confounding by population group here, since each clinical subset includes all 4 population groups, but in differing proportions (see Discussion).

(iv) Comparison with original study results

Figure 4 illustrates salient differences between the omnibus results and results extracted from the original published linkage analyses of the individual studies. The 10% PPL threshold was chosen based on qualitative visual separation of salient signals from background noise in Figure 1, and intended to mimic the criterion of “suggestive” evidence as shown in the figure based on the original publications. There is no rigorous way to precisely compare the magnitude of results across data analytic methods, or to derive and apply exactly comparable interval estimates. Thus the figure is intended to convey in broad strokes differences in the overall genomic landscape between the individual original reports and our current omnibus analyses, rather than to present precise quantitative differences.

Of the 20 intervals with PPL > 0.10, 12 line up in or near an originally reported interval. This could be coincidental, however, since all but 3 chromosomes are implicated (generally at the level of “suggestive” linkage) by at least one of the original publications, with little overlap in reported loci across the original studies. Figure 4 also shows the large portions of the genome showing evidence *against* linkage using the PPL. The PPL’s ability to accumulate evidence against linkage has no correlate in either the original NPL or meta analyses.

(v) Comparison with results from independent studies

Of the 4 omnibus loci with PPL over 25%, all are in regions of previous schizophrenia linkage reports. Chromosome 2q36.1 is in a region that has been implicated in several prior linkage reports, including a significant finding in a Finnish sample (23), and suggestive support from other reports (5, 24, 25) which include families found in Study 2 and Study 3. *SCG2*, the gene encoding secretogranin II, is located under the center of this peak and has been reported to have increased expression in the dorsolateral prefrontal cortex in individuals with schizophrenia (26). Chromosome 3q28 is supported by suggestive linkage results in studies in Finnish (23), Palauan (27), and Dagestan (28) samples that are not part of the NIMH-HGI collection. Chromosome 12q23.1 has been implicated by a suggestive linkage report with a negative symptom factor score (29). While the 12q candidate gene *DAO* is located beyond the boundaries of this peak, in an area where the omnibus analysis produced evidence against linkage, the gene *PAH* is located near the edge of the omnibus peak, in a region with PPL scores slightly above 2%. *PAH*, the gene for phenylalanine

hydroxylase, while traditionally associated with phenylketonuria, has been suggested as a schizophrenia candidate gene in multiple studies (29–33). Of further interest is the 12q linkage peak observed in the African American subset; this peak has a maximum PPL score of 25.4% located 4 cM telomeric to the omnibus peak, very near *PAH*. The omnibus peak on chromosome 15q23 overlays a suggestive linkage peak that was originally reported in the Hispanic samples included in this analysis (8).

Four additional peaks over 25% were observed in specific population groups. The 10q22.3 and 10q26.12 peaks in the Han Chinese sample overlap the linked regions from the original report on these families (5). Similarly, the Hispanic-specific peak at 5p14.1 overlaps a suggestive linkage peak that was previously reported in these families (8). By contrast, the 1p32.3 locus seen in the European American subset was not suggested by the individual studies contributing to this subset (4, 34, 35). Having one population group give evidence for linkage and the other groups give combined evidence against is consistent with either separate sets of genes operating in the different population groups, or, more likely, dependence of the salience of genetic effects on the background (ancestral) genome and/or environment. It is also consistent, however, with the subset-specific PPLs being over-estimates of the actual probability of linkage, which is given by the omnibus PPL. Differences in sample sizes across groups (139 African American, 187 European American, 483 Han Chinese, and 161 Hispanic) also complicate interpretation.

Dividing the data by clinical subgroup (families containing individuals with Schizophrenia/Affective vs. families with only narrow Schizophrenia) yielded 4 additional loci with PPL over 25%, and in every case the locus was supported by one group while the other group gave evidence against linkage. This strongly suggests that the genetics of schizophrenia in families characterized by the presence of schizoaffective disorder or schizophrenia with comorbid affective disorder may be distinct from the genetics of schizophrenia in individuals without a significant mood disorder. On the other hand, there is considerable confounding by population, since the preponderance of families with individuals with a Schizophrenia/Affective diagnosis varies by group as well. The distribution of groups (African American, European American, Han Chinese, Hispanic) within Schizophrenia only families and families that include Schizophrenia/Affective are (.11, .15, .59, .15) and (.28, .41, .04, .26), respectively.

Quite interestingly, however, all three locations identified in the families with Schizophrenia/Affective (11p15.3, 11p11.2, and Xq26.1) have been previously implicated in linkage or association studies using samples with bipolar disorder or mixed samples with schizophrenia and bipolar disorder (36–40). The 11p15.3 region was also reported as a main finding in the original publication for Study 7 (9), and indeed the African American-specific PPL reaches 15% at 28 cM. Of particular note is that (9) reported a marked strengthening of the linkage signal at 11p15.3 when using a phenotype that included schizophrenia and schizoaffective disorder rather than schizophrenia only. Finally, the Schizophrenia subset produced a peak of 46% at 6q14.1 that overlaps a peak of 26% in the European American subgroup, but was not reported by any of the original European American studies. In aggregate these results have significant implications for the inclusion of individuals with

schizoaffective disorder in linkage or association studies of schizophrenia. (See also SA3 for a comparison with results in the NHRGI GWAS database.)

Insofar as population is a major source of heterogeneity in these analyses, it is noteworthy that, with the exception of the Han Chinese sample, the remaining sample sizes for the different groups remain quite small. It is not surprising, therefore, that even the largest PPLs remain moderate in size. Similarly, dividing the data based on the presence of affective illness results in a far smaller subset for the group containing Schizophrenia/Affective diagnoses. Strikingly, however, this group also produces some of the highest PPLs. Our results suggest that both population and clinical subgroup are key classifiers for purposes of gene mapping. Ideally, we would like to subset simultaneously on both criteria. However, the extremely small subsets that would result preclude this approach.

It is also of interest to compare our results with the meta-analyses of Ng et al. (41) and Nato et al. (42), both of which have included studies from the HGI collection as well as other studies. Nato et al. identified 22 regions of interest, while Ng et al. reported 8 regions with aggregate genome-wide evidence for linkage, all of which overlap with regions identified by Nato et al. While the majority of the Ng (5 of 8) and Nato (13 of 22) regions produced some level of evidence in favor of linkage under the omnibus analysis, only two of our four omnibus peaks >25% (2q36.1 and 3q28) overlapped a region of interest from either study, with our largest peak of 41% overlapping regions of interest from both studies. Of our 8 peaks >25% that were specific to an ethnic or clinical subset, only two (5p14.1 and 10q26.12) overlapped a region of interest from either study, again with the larger peak of 34% overlapping regions of interest from both studies. See ST4 for detailed comparisons.

Discussion

Our re-analyses of HGI data present a picture of the schizophrenia genome with some overlap with previous reports but also some novel loci, with differences both in terms of the specific loci implicated and also the rank ordering of these loci by relative strength of evidence. While a number of loci previously implicated using the samples from the HGI were also identified in the current analyses, such as 2q36.1 and 15q23, others were not. At the same time, several loci not previously reported in the HGI samples but supported by other reports in the literature have now been identified in the HGI collection, such as 3q28 and 12q23.1. Loci without any prior linkage reports in schizophrenia but with positional support from association studies were also identified, such as 11p11.2 and Xq26.1. Differences in the genetics of schizophrenia across population groups and in families with differing amounts of affective illness were also highlighted, in particular, with 11p15.3, 11p11.2, and Xq26.1 - which are prominent in the Schizophrenia/Affective group, overlapping with loci reported from independent studies of bipolar disorder or mixed bipolar-schizophrenia samples.

One caveat is that we have employed a highly conservative approach both in deciding who to call "affected" (e.g. narrow Schizophrenia with multiple exclusion criteria) and in our inclusion criteria for families (at least one case of Schizophrenia plus one additional Schizophrenia or Schizophrenia/Affective), which led us to drop a large number of families

from these analyses. While we believe that this approach is justified, particularly when attempting to make “apples to apples” comparisons across multiple different studies, nevertheless we are aware that other investigators might make quite different judgment calls regarding these decisions. All data on the full set of families, including those we did not analyze here, are available on the HGI website (nimhgenetics.org), as are all protocols used in preparing the data files (<https://www.nimhgenetics.org/projects/CAPS>). We hope that other investigators will find this a useful resource for carrying out their own analyses.

A second possible caveat is that we have relied on linkage analysis. Given the relative paucity of validated linkage findings in psychiatric genetics, it is not unreasonable to be skeptical regarding this approach. There is a certain irony here, because past failures may in part be attributable to the fact that psychiatry was an early and enthusiastic endorser of the technique. The SZ data considered here date back in some cases to the 1990's, and the original studies taken individually were almost certainly underpowered for a variety of reasons. By revisiting the HGI data and applying modern data processing and newer data analytic methods to the existing multi-site data as a whole, we believe that we have succeeded in extracting new information from older sets of families. Of course we have also lost something in working with the repository data, insofar as the original investigators had access to additional clinical information.

Historically there have been few gene discoveries under psychiatric linkage peaks. In this regard, too, having been a leader in methods development put the field of psychiatric genetics ahead of its time: earlier molecular techniques were cumbersome and expensive, and combined with the width of linkage peaks from the older studies, this made gene identification under the peaks impractical. But the increasing practicality of high-throughput DNA sequencing should support gene discovery at linked loci in a manner unavailable until very recently. Indeed, human genetics is returning to a focus on “co-segregation” (i.e., linkage analysis) as a critical adjuvant to whole genome sequencing, because narrowing the search down to only those portions of the genome showing evidence of linkage dramatically reduces the amount of sequence needing to be interrogated. One could even argue that linkage analysis as a technique for gene discovery has yet to be properly applied in much of psychiatric genetics.

Linkage analysis and association analysis (whether to common SNPs or rare variants) have power to detect very different types of genetic effects: GWAS is well adapted to finding common variants conferring low relative risks in a manner that is consistent across populations (43) (requiring independent replication ensures that effects specific to one data set are discounted (44)); while linkage analysis is adapted to finding loci containing genes of large effect (in general, with rarer allele frequencies and much higher genotypic relative risks), and particularly when conducted using statistical methods specifically tuned for such conditions, it can find such genes even when they are causally relevant only in a subset of families (10). One reason to continue to search for such genes is precisely because a gene discovered by linkage analysis almost certainly is a gene of large effect, albeit perhaps only in some families. Such genes may yield different insights into gene pathways and networks than genes discovered through alternative study designs. Linkage analysis is also robust to allelic heterogeneity, which can eliminate allelic associations altogether (45).

The genetic architecture for complex disorders likely involves many different types of effects simultaneously: major gene effects in subsets of families; common background genes conferring small risks; copy number variants, perhaps particularly important in causing sporadic forms of disease; extensive locus heterogeneity, which might or might not be alleviated by refined clinical subtyping; and more complex features including gene $\times$ gene and gene $\times$ environment interactions, epigenetics, and probably other things we have not even thought of yet. Under such circumstances, no one study design can solve all problems.

The psychiatric genetics community has an enormous resource on hand: extensive collections of multiplex families with considerable clinical information. These collections were labor-intensive and expensive to amass; by contrast, the cost of genotyping or even sequencing is (becoming) relatively small. Returning to these collections with the benefits of hindsight seems a promising and cost-effective way to contribute to the growing understanding of genetic architecture emerging from a multitude of studies and study designs all being considered simultaneously. We have tried here to illustrate the potential of such use of retrospective data to alter and augment contemporary understanding of genetic underpinnings of psychiatric disorders. Of course, interpretation of the results is still hampered by the very limited information content afforded by the available genotype data.

Finally, we note an important methodological issue highlighted by these results, namely, that conventional interpretations of statistical significance in terms of independent replication can lead us to overlook important loci that may have salient effects only in subsets of the data. As is well known, failure to replicate true loci is to be expected for even moderately complex disorders (46). What is perhaps less widely appreciated is that traditional meta-analysis will tend to fail in precisely those same circumstances where independent replication cannot be relied upon for confirmation of results (17, 18). At the same time, we are appropriately skeptical of weak findings that fail to replicate. Indeed, as the literature accumulates reports of weak signals obtained by individually underpowered studies, and particularly in view of the failure of standard statistical methods to appropriately indicate evidence *against* linkage, the overall picture of the schizophrenia genome becomes murkier, not clearer, as time goes on.

By design, repositories such as the HGI offer a solution, by permitting analysis of far larger quantities of data than can be collected by any one study. However, under exactly these same conditions of underlying genetic complexity, so-called “mega-analyses,” which simply pool all data into a single file for analysis, can also end up washing out important, subset-specific loci, by failing to appropriately allow for inter-data set heterogeneity. For these reasons, we view the PPL - which does not require agreement across all data subsets, but rather, accumulates the aggregate evidence both for or against linkage in a mathematically rigorous manner while allowing for between-data set differences - as particularly well-suited to the task of accurately and efficiently extracting genetic information from repository collections. With the advent of affordable sequence data, we predict that revisiting family data already amassed in the HGI will provide a cost-effective mechanism not just for discovering linkage peaks, but for fine-mapping these peaks down to the level of the individual gene or variant.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by National Institutes of Health grants R01 MH086117 and U24 MH068457. We are grateful to our Clinical Advisory Board for valuable contributions: Anne Bassett, Prudence Fisher, Ellen Leibenluft, Deborah Levy, Michel Maziade, Kathleen Merikangas, Joe Piven, and Peter Szatmari. John Burian and William Valentine-Cooper contributed extensive and essential programming support. We also wish to thank the investigators who contributed these data sets to the HGI and the families who participated in these studies, without whom this work would not have been possible, as well as HGI staff at Washington University for their assistance throughout the data review process.

References

1. Vieland VJ, Huang Y, Seok SC, Burian J, Catalyurek U, O'Connell J, et al. KELVIN: a software package for rigorous measurement of statistical evidence in human genetics. *Human Heredity*. [Research Support, N.I.H., Extramural]. 2011; 72(4):276–88.
2. Kaufmann CA, Suarez B, Malaspina D, Pepple J, Svrakic D, Markel PD, et al. NIMH Genetics Initiative Millenium Schizophrenia Consortium: linkage analysis of African-American pedigrees. *Am J Med Genet*. 1998 Jul 10; 81(4):282–9. [PubMed: 9674972]
3. Faraone SV, Matise T, Svrakic D, Pepple J, Malaspina D, Suarez B, et al. Genome scan of European-American schizophrenia pedigrees: results of the NIMH Genetics Initiative and Millennium Consortium. *Am J Med Genet*. 1998 Jul 10; 81(4):290–5. [PubMed: 9674973]
4. Suarez BK, Duan J, Sanders AR, Hinrichs AL, Jin CH, Hou C, et al. Genomewide linkage scan of 409 European-ancestry and African American families with schizophrenia: Suggestive evidence of linkage at 8p23.3-p21.2 and 11p13.1-q14.1 in the combined sample. *Am J Hum Genet*. 2006 Feb; 78(2):315–33. [PubMed: 16400611]
5. Faraone SV, Hwu HG, Liu CM, Chen WJ, Tsuang MM, Liu SK, et al. Genome scan of Han Chinese schizophrenia families from Taiwan: confirmation of linkage to 10q22.3. *Am J Psychiatry*. 2006 Oct; 163(10):1760–6. [PubMed: 17012687]
6. Almasy L, Gur RC, Haack K, Cole SA, Calkins ME, Peralta JM, et al. A genome screen for quantitative trait loci influencing schizophrenia and neurocognitive phenotypes. *Am J Psychiatry*. [Research Support, N.I.H., Extramural]. 2008 Sep; 165(9):1185–92.
7. Escamilla MA, Ontiveros A, Nicolini H, Raventos H, Mendoza R, Medina R, et al. A genome-wide scan for schizophrenia and psychosis susceptibility loci in families of Mexican and Central American ancestry. *American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics*. [Research Support, N.I.H., Extramural]. 2007 Mar 5; 144B(2):193–9.
8. Escamilla M, Hare E, Dassori AM, Peralta JM, Ontiveros A, Nicolini H, et al. A schizophrenia gene locus on chromosome 17q21 in a new set of families of Mexican and central american ancestry: evidence from the NIMH Genetics of schizophrenia in latino populations study. *Am J Psychiatry*. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2009 Apr; 166(4):442–9.
9. Wiener HW, Klei L, Irvin MD, Perry RT, Aliyu MH, Allen TB, et al. Linkage analysis of schizophrenia in African-American families. *Schizophrenia research*. [Comparative Study Research Support, N.I.H., Extramural]. 2009 Apr; 109(1–3):70–9.
10. Govil M, Vieland VJ. Practical considerations for dividing data into subsets prior to PPL analysis. *Hum Hered*. 2008; 66:223–37. [PubMed: 18612207]
11. Vieland VJ, Huang Y, Bartlett C, Davies TF, Tomer Y. A Multilocus Model of the Genetic Architecture of Autoimmune Thyroid Disorder, with Clinical Implications. *American journal of human genetics*. 2008; 82(6):1349–56. [PubMed: 18485327]
12. Vieland VJ, Hallmayer J, Huang Y, Pagnamenta AT, Pinto D, Khan H, et al. Novel method for combined linkage and genome-wide association analysis finds evidence of distinct genetic

- architecture for two subtypes of autism. *J Neurodev Disord.* 2011 Jan 19; 3(2):113–23. [PubMed: 21484201]
13. Wratten NS, Memoli H, Huang Y, Dulencin AM, Matteson PG, Cornacchia MA, et al. Identification of a schizophrenia-associated functional noncoding variant in NOS1AP. *Am J Psychiatry.* 2009 Apr; 166(4):434–41. [PubMed: 19255043]
 14. Smith CAB. Testing for heterogeneity of recombination fraction values in human genetics. *Ann Hum Genet.* 1963; 27:175–82. [PubMed: 14081488]
 15. Vieland VJ, Wang K, Huang J. Power to detect linkage based on multiple sets of data in the presence of locus heterogeneity: comparative evaluation of model-based linkage methods for affected sib pair data. *Human Heredity.* 2001; 51(4):199–208. [PubMed: 11287741]
 16. Huang J, Vieland VJ. Comparison of ‘model-free’ and ‘model-based’ linkage statistics in the presence of locus heterogeneity: single data set and multiple data set applications. *Human Heredity.* 2001; 51(4):217–25. [PubMed: 11287743]
 17. Greenberg DA. Summary of analyses of problem 2 simulated data for GAW 11. *Genet Epidemiol.* 1999; 17(Suppl 1):S449–59. [PubMed: 10597475]
 18. Huang Y, Vieland VJ. Association statistics under the PPL framework. *Genet Epidemiol.* 2010 Dec; 34(8):835–45. [PubMed: 21058335]
 19. Elston RC, Lange K. The prior probability of autosomal linkage. *Ann Hum Genet.* 1975 Jan; 38(3):341–50. [PubMed: 1137348]
 20. Royall, R. *Statistical Evidence: A likelihood paradigm.* London: Chapman & Hall; 1997.
 21. Vieland VJ, Hodge SE. Review of Statistical Evidence: A Likelihood Paradigm. *Am J Hum Genet.* 1998; 63:283–9.
 22. Vieland VJ. Thermometers: something for statistical geneticists to think about. *Hum Hered.* 2006; 61(3):144–56. [PubMed: 16770079]
 23. Paunio T, Ekelund J, Varilo T, Parker A, Hovatta I, Turunen JA, et al. Genome-wide scan in a nationwide study sample of schizophrenia families in Finland reveals susceptibility loci on chromosomes 2q and 5q. *Hum Mol Genet.* 2001 Dec 15; 10(26):3037–48. [PubMed: 11751686]
 24. Holmans PA, Riley B, Pulver AE, Owen MJ, Wildenauer DB, Gejman PV, et al. Genomewide linkage scan of schizophrenia in a large multicenter pedigree sample using single nucleotide polymorphisms. *Mol Psychiatry.* 2009; 14(8):786–95. [PubMed: 19223858]
 25. Williams NM, Norton N, Williams H, Ekholm B, Hamshere ML, Lindblom Y, et al. A systematic genomewide linkage study in 353 sib pairs with schizophrenia. *Am J Hum Genet.* 2003 Dec; 73(6):1355–67. [PubMed: 14628288]
 26. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. *Proc Natl Acad Sci U S A.* 2001 Apr 10; 98(8):4746–51. [PubMed: 11296301]
 27. Klei L, Bacanu SA, Myles-Worsley M, Galke B, Xie W, Tiobech J, et al. Linkage analysis of a completely ascertained sample of familial schizophrenics and bipolars from Palau, Micronesia. *Hum Genet.* 2005 Aug; 117(4):349–56. [PubMed: 15915326]
 28. Bulayeva KB, Glatt SJ, Bulayev OA, Pavlova TA, Tsuang MT. Genome-wide linkage scan of schizophrenia: a cross-isolate study. *Genomics.* 2007 Feb; 89(2):167–77. [PubMed: 17140763]
 29. Wilcox MA, Faraone SV, Su J, Van Eerdewegh P, Tsuang MT. Genome scan of three quantitative traits in schizophrenia pedigrees. *Biol Psychiatry.* 2002 Nov 1; 52(9):847–54. [PubMed: 12399137]
 30. Bergen SE, Fanous AH, Walsh D, O’Neill FA, Kendler KS. Polymorphisms in SLC6A4, PAH, GABRB3, and MAOB and modification of psychotic disorder features. *Schizophr Res.* 2009 Apr; 109(1–3):94–7. [PubMed: 19268543]
 31. Chao HM, Richardson MA. Aromatic amino acid hydroxylase genes and schizophrenia. *Am J Med Genet.* 2002 Aug 8; 114(6):626–30. [PubMed: 12210276]
 32. Richardson MA, Read LL, Clelland JD, Chao HM, Reilly MA, Romstad A, et al. Phenylalanine hydroxylase gene in psychiatric patients: screening and functional assay of mutations. *Biol Psychiatry.* 2003 Mar 15; 53(6):543–53. [PubMed: 12644360]
 33. Talkowski ME, McClain L, Allen T, Bradford LD, Calkins M, Edwards N, et al. Convergent patterns of association between phenylalanine hydroxylase variants and schizophrenia in four

- independent samples. *Am J Med Genet B Neuropsychiatr Genet.* 2009 Jun 5; 150B(4):560–9. [PubMed: 18937293]
34. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, et al. Common variants conferring risk of schizophrenia. *Nature.* [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2009 Aug 6; 460(7256):744–7.
 35. Cloninger CR, Kaufmann CA, Faraone SV, Malaspina D, Svrakic DM, Harkavy-Friedman J, et al. Genome-wide search for schizophrenia susceptibility loci: the NIMH Genetics Initiative and Millennium Consortium. *Am J Med Genet.* 1998 Jul 10; 81(4):275–81. [PubMed: 9674971]
 36. Wang KS, Liu XF, Aragam N. A genome-wide meta-analysis identifies novel loci associated with schizophrenia and bipolar disorder. *Schizophrenia research.* [Meta-Analysis Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural]. 2010 Dec; 124(1–3):192–9.
 37. Huang J, Perlis RH, Lee PH, Rush AJ, Fava M, Sachs GS, et al. Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. *Am J Psychiatry.* [Comparative Study Research Support, N.I.H., Extramural]. 2010 Oct; 167(10):1254–63.
 38. Middleton FA, Pato MT, Gentile KL, Morley CP, Zhao X, Eisener AF, et al. Genomewide linkage analysis of bipolar disorder by use of a high-density single-nucleotide-polymorphism (SNP) genotyping assay: a comparison with microsatellite marker assays and finding of significant linkage to chromosome 6q22. *Am J Hum Genet.* 2004 May; 74(5):886–97. [PubMed: 15060841]
 39. Berrettini W. Progress and pitfalls: bipolar molecular linkage studies. *J Affect Disord.* 1998 Sep; 50(2–3):287–97. [PubMed: 9858089]
 40. Wigg K, Feng Y, Gomez L, Kiss E, Kapornai K, Tamas Z, et al. Genome scan in sibling pairs with juvenile-onset mood disorders: Evidence for linkage to 13q and Xq. *Am J Med Genet B Neuropsychiatr Genet.* 2009 Jul 5; 150B(5):638–46. [PubMed: 19035515]
 41. Ng MY, Levinson DF, Faraone SV, Suarez BK, DeLisi LE, Arinami T, et al. Meta-analysis of 32 genome-wide linkage studies of schizophrenia. *Mol Psychiatry.* 2009 Aug; 14(8):774–85. [PubMed: 19349958]
 42. Nato, A.; Kong, X.; Chen, F.; He, C.; Chimento, D.; Byrne, B., et al. Genomic Characterization of Schizophrenia Candidate Gene Regions. American Society of Human Genetics Annual Meeting; Hawaii. 2009.
 43. Hodge SE. What association analysis can and cannot tell us about the genetics of complex disease. *Am J Med Genet.* 1994 Dec 15; 54(4):318–23. [PubMed: 7726203]
 44. Vieland VJ. The replication requirement. *Nat Genet.* 2001 Nov; 29(3):244–5. [PubMed: 11687787]
 45. Slager SL, Huang J, Vieland VJ. Effect of allelic heterogeneity on the power of the transmission disequilibrium test. *Genet Epidemiol.* 2000 Feb; 18(2):143–56. [PubMed: 10642427]
 46. Suarez, BK.; Hampe, CL.; VanEerdewegh, P. Problems of replicating linkage claims in psychiatry. In: Gershon, ES.; Cloninger, CR., editors. *Genetic Approaches in Mental Disorders.* Washington, DC: American Psychiatric Press; 1994. p. 23–46.

Figure 1.

Omnibus Linkage Results

The PPL is on the probability scale (0,...,1.0); values < 2% (horizontal line) indicate evidence against linkage, while values > 2% indicate (some degree of) evidence in favor of linkage.

Figure 2.
Linkage Results by Population Groups

Figure 3.
Linkage Results by Clinical Subgroups

Figure 4.

Linkage Findings for CAPS and Compared to Original Reports

Thresholds and intervals for inclusion of original signals were taken directly from published reports, and generally correspond to “suggestive” linkage. Where intervals were not reported, the average reported interval of 16 cM was imposed. Omnibus PPL results are shown above the dotted line. “CAPS FOR” includes all regions with PPL > 10%. This threshold was selected to similarly reflect what might correspond to a “suggestive” level of support. “CAPS AGAINST” includes all regions with PPL < 2% (evidence against linkage). Note also that due to the low resolution of genetic scale in this figure, no attempt was made to harmonize the genetic maps across the original reports; different studies reported their results on Rutgers, Marshfield, Genethon, and GLDB maps.

Table 1

Primary Linkage Findings¹

Locus	cM ²	Omnibus	African American	European American	Han Chinese	Hispanic	Schizophrenia/ Affective Families	Schizophrenia Families
1p32.3	80	0.06	0.015	0.27	0.010	0.014	0.02	0.06
2q36.1	230	0.41	0.05	0.02	0.02	0.18	0.16	0.07
3q28	210	0.27	0.03	0.15	0.02	0.03	0.18	0.03
5p14.1	48	0.20	0.04	0.019	0.010	0.26	0.09	0.04
6q14.1-q15	94	0.10	0.017	0.11*	0.018	0.03	0.000	0.46
10q22.3	98	0.04	0.015	0.009	0.36	0.009	0.009	0.11
10q26.12	144	0.04	0.010	0.008	0.34	0.015	0.010	0.09
11p15.3	22	0.12	0.10	0.02	0.015	0.04	0.30	0.009
11p11.2	68	0.14	0.06	0.09	0.014	0.016	0.36	0.008
12q23.1-q23.2	112	0.26	0.08*	0.03	0.02	0.04	0.017	0.30*
15q23	72	0.27	0.02	0.03	0.02	0.18	0.10	0.06
Xq26.1	146	0.011	0.04	0.012	0.010	0.02	0.27	0.000

Shown here are PPLs for all loci with PPL over 0.25 in at least one subsample. The highest PPL per row is shown in bold. By convention, PPL $\geq 2\%$ are reported to 2 decimal places; PPL $< 2\%$ to three. Asterisks (*) indicate instances in which a subgroup peak is close to but not directly over the omnibus peak: on chromosome 6, the European American peak is PPL=0.256 at 104 cM; on chromosome 12, African American and Schizophrenia peaks at 116 cM are PPL=0.254 and PPL=0.356, respectively.

² Genetic positions refer to hg19 Build 37. When the PPL exceeds 0.25 in multiple subgroups, the position shown is from the omnibus scan if omnibus PPL > 0.25 , or for the subgroup with the largest PPL otherwise.